Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Edoxaban for Patients with Atrial Fibrillation and Previous Brain Bleeding

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on patients who have experienced a type of bleeding in the brain known as intracranial hemorrhage and also have a heart condition called atrial fibrillation. The study is investigating the effects of a medication called edoxaban, which is available in 60 mg and 30 mg doses as film-coated tablets. Edoxaban is a type of blood thinner that helps prevent blood clots. The purpose of the study is to determine if edoxaban can reduce the risk of stroke or other blood clot-related issues in these patients compared to those who are not taking any blood thinners or are on a different type of medication called antiplatelet therapy.

Participants in the study will be randomly assigned to receive either edoxaban or a placebo, which is a pill that looks like the medication but does not contain any active ingredients. The study will last for a period of 12 weeks, during which participants will take their assigned tablets daily. Throughout the study, participants will be monitored for any signs of stroke, blood clots, or bleeding events. The goal is to see if edoxaban is effective and safe for people with atrial fibrillation who have had a previous intracranial hemorrhage.

By participating in this study, researchers hope to gather important information that could help improve treatment options for patients with atrial fibrillation and a history of brain bleeding. The findings may lead to better ways to prevent strokes and other complications in this high-risk group of patients. The study is expected to be completed by April 2026.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will provide written informed consent, confirming your understanding and agreement to participate.

    You must be at least 45 years old and have a history of a specific type of brain bleed, known as intracranial hemorrhage, and a condition called atrial fibrillation, which affects the heart's rhythm.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility based on your medical history and current health status.

    Your CHA2DS2-VASc score, which helps assess the risk of stroke, must be 2 or higher.

  3. Step 3

    Medication administration

    You will be assigned to receive either edoxaban or a non-anticoagulant medical therapy. Edoxaban is taken orally in the form of film-coated tablets.

    The dosage of edoxaban will be either 60 mg or 30 mg, taken once daily. The specific dosage will be determined by the study team.

  4. Step 4

    Ongoing monitoring

    Throughout the study, regular monitoring will be conducted to assess your health and any effects of the medication.

    This includes checking for any signs of stroke, systemic embolism, or major bleeding, which are key focus areas of the study.

  5. Step 5

    Follow-up visits

    You will attend scheduled follow-up visits to evaluate your progress and any changes in your condition.

    These visits will help track the effectiveness and safety of the treatment you are receiving.

  6. Step 6

    Completion of study

    The study is expected to conclude by April 30, 2026. At the end of the study, a final assessment will be conducted.

    The results will contribute to understanding the impact of edoxaban on reducing the risk of stroke and other complications in patients with your medical history.

Who can join the trial?

10 criteria

  • Provide written informed consent, which means you agree to participate after understanding the study details.
  • Be 45 years or older at the time of signing the consent form.
  • Have had a previous intracranial hemorrhage, which is a type of bleeding inside the skull. This includes:
    • Bleeding that was symptomatic (caused noticeable symptoms).
    • Bleeding that was spontaneous (happened on its own) and non-traumatic (not caused by an injury).
    • Bleeding that was non-lobar intraparenchymal (inside the brain tissue) or intraventricular (inside the brain's fluid spaces).
    • Bleeding that was symptomatic spontaneous or non-penetrating traumatic subdural (under the outer covering of the brain).
    • Have documented atrial fibrillation, which is a type of irregular heartbeat. This can be:
      • Paroxysmal (comes and goes).
      • Persistent (lasts longer than a week).
      • Permanent (ongoing).
      • Have a CHA2DS2-VASc score of 2 or higher. This is a medical score used to determine the risk of stroke in people with atrial fibrillation.

Who cannot join the trial?

8 criteria

  • Patients who have a history of **intracranial hemorrhage** (bleeding inside the skull) cannot participate.
  • Patients who are not considered **high risk** for atrial fibrillation, as determined by a specific scoring system, are excluded.
  • Patients who are currently on **anticoagulant therapy** (medication that prevents blood clots) other than the study medication are not eligible.
  • Patients who are unable to take the study medication due to allergies or other medical reasons cannot join the study.
  • Patients with certain medical conditions that the study doctors believe would make participation unsafe are excluded.
  • Patients who are pregnant or breastfeeding are not allowed to participate.
  • Patients who are part of another clinical trial at the same time are not eligible.
  • Patients who are unable to follow the study procedures or attend study visits are excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Edoxaban is a medication used in this clinical trial. It is a type of blood thinner, which means it helps prevent blood clots from forming in your body. This is important for people with atrial fibrillation, a condition where the heart beats irregularly, because they are at a higher risk of having a stroke. In this study, edoxaban is being tested to see if it can reduce the risk of stroke or other serious blood clot-related problems in people who have had a brain bleed in the past.

Nonanticoagulant medical therapy is another approach being studied in this trial. This means that instead of using blood thinners like edoxaban, participants may receive either no medication to prevent blood clots or a different type of medication called antiplatelet therapy. Antiplatelet therapy works by stopping blood cells called platelets from sticking together and forming clots. This option is being compared to edoxaban to see which is more effective at reducing the risk of stroke or other blood clot-related issues in people with atrial fibrillation who have previously experienced a brain bleed.

What is already known about the treatment

Edoxaban – Edoxaban is a medication taken orally in the form of a tablet, typically administered once daily. It is currently being studied in clinical trials for its effectiveness in patients with atrial fibrillation who have previously experienced bleeding in the brain. The main purpose of edoxaban is to reduce the risk of stroke or blood clots in these high-risk patients. It works by inhibiting a specific protein in the blood that is involved in clot formation, thereby preventing clots from forming. Edoxaban belongs to a class of drugs known as anticoagulants, which are commonly referred to as blood thinners.

Investigated diseases

Atrial Fibrillation – Atrial fibrillation is a heart condition characterized by an irregular and often rapid heart rate. It occurs when the upper chambers of the heart (atria) beat out of coordination with the lower chambers (ventricles). This can lead to poor blood flow and the formation of blood clots in the heart. Over time, atrial fibrillation can cause symptoms such as palpitations, shortness of breath, and fatigue. The condition can be persistent or come and go, and it may increase the risk of stroke and other heart-related complications. It is often associated with other heart conditions and risk factors like high blood pressure and diabetes.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-518508-31-00Protocol codeENRICH-AFEstimated enrolment950 patientsSponsorHamilton Health Sciences Corporation

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.